Search tips
Search criteria 


Logo of annrheumdAnnals of the Rheumatic DiseasesVisit this articleSubmit a manuscriptReceive email alertsContact usBMJ
Ann Rheum Dis. 2005 April; 64(4): 620–625.
PMCID: PMC1755456

Controlled clinical trial of IV cyclophosphamide versus IV methylprednisolone in severe neurological manifestations in systemic lupus erythematosus


Background: Severe neurological involvement in systemic lupus erythematosus (NPSLE) is one of the most dreadful complications of the disease.

Objective: To identify the best drug, dose, and treatment.

Patients and methods: The study was a controlled clinical trial at two tertiary care centres of patients with SLE according to the ACR criteria, with incident (no more than 15 days) onset of severe NP manifestations such as seizures, optic neuritis, peripheral or cranial neuropathy, coma, brainstem disease, or transverse myelitis. Induction treatment with 3 g of IV methylprednisolone (MP) followed by either IV monthly cyclophosphamide (Cy) versus IV MP bimonthly every 4 months for 1 year and then IV Cy or IV MP every 3 months for another year. The primary end point was response to treatment: at least 20% improvement from basal conditions on clinical, laboratory, or specific neurological testing variables.

Results: Overall, a response rate of 75% was observed. Of the 32 patients studied, 18/19 receiving Cy and 7/13 receiving MP responded to treatment (p<0.03).

Conclusions: Cy seems to be more effective than MP in the treatment of acute, severe NPSLE.

Figure 1
 Patient's outcome throughout follow up.
Figure 2
 Mean number of seizures/month in (A) MP group; (B) Cy group.
Figure 3
 Changes in visual analogue scale for sensitivity in transverse myelitis and peripheral neuropathy.
Figure 4
 Changes in visual analogue scale for muscular strength in transverse myelitis and peripheral neuropathy.

Articles from Annals of the Rheumatic Diseases are provided here courtesy of BMJ Publishing Group